A retrospective pooled analysis of duloxetine safety in 23 983 subjects

References

• Pitsikas N. Duloxetine Eli Lilly & Co. Curr Opin Investig Drugs 2000;1:116–21
   PubMedGoogle Scholar
• Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 2002;58:169–222
   PubMedGoogle Scholar
• Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984;7:309–38
   PubMed Web of Science ®Google Scholar
• Clark FM, Proudfit HK. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception. Brain Res 1993;616:200–10
   PubMed Web of Science ®Google Scholar
• Coderre TJ, Katz J. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci 1997;20:404–19
   PubMed Web of Science ®Google Scholar
• Thor KB, Hisamitsu T, de Groat WC. Unmasking of a neonatal somatovesical reflex in adult cats by the serotonin autoreceptor agonist 5-methoxy-N,N-dimethyltryptamine. Brain Research 1990;54: 35–42
   Google Scholar
• Espey MJ, Downie JW, Fine A. Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats. Eur J Pharmacol 1992;221: 167–70
   Google Scholar
• Danuser H, Thor KB. Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Br J Pharmacol 1996;118:150–4
   PubMed Web of Science ®Google Scholar
• Krier J, Thor KB, de Groat WC. Effects of clonidine on the lumbar sympathetic pathways to the large intestine and urinary bladder of the cat. Eur J Pharmacol 1979;59:47–53
   Google Scholar
• Pedersen E, Torring J, Klemar B. Effect of the alpha-adrenergic blocking agent thymoxamine on the neurogenic bladder and urethra. Acta Neurol Scand 1980;61:107–14
   Google Scholar
• Gajewski J, Downie JW, Awad SA. Experimental evidence for a central nervous system site of action in the effect of alpha-adrenergic blockers on the external urinary sphincter. J Urol 1984;132:403–9
   Google Scholar
• Downie JW, Bialik GJ. Evidence for a spinal site of action of clonidine on somatic and viscerosomatic reflex activity evoked on the pudendal nerve in cats. J Pharmacol Exp Ther 1988;246:352–8
   PubMed Web of Science ®Google Scholar
• Downie JW, Espey MJ, Gajewski JB. Alpha 2-adrenoceptors not imidazole receptors mediate depression of a sacral spinal reflex in the cat. Eur J Pharmacol 1991;195: 301–4
   Google Scholar
• Hurley D, Turner CL, Yalcin I, Viktrup L, et al. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol 2006;125:120–8
   PubMed Web of Science ®Google Scholar
• Raskin J, Pritchett YL, Wang F, D’Souza DN, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346–56
   Google Scholar
• Arnold LM, Rosen A, Pritchett YL, D’Souza DN, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5–15
   Google Scholar
• Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005;20:327–41
   PubMed Web of Science ®Google Scholar
• Cymbalta [package insert]. Indianapolis, IN, USA. Eli Lilly & Company, 2005
   Google Scholar
• Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999;20:277–87
   PubMed Web of Science ®Google Scholar
• Bump R, Yalcin I, Voss S. The effect of duloxetine dose escalation and tapering on the incidence of adverse events (AE) in women with stress urinary incontinence. Neurourol Urodyn 2005;24:116
   Google Scholar
• Dunner DL, Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg QD starting doses. Curr Ther Res 2005;66:1–19
   PubMedGoogle Scholar
• Navarro VJ, Senior JR. Drug-Related Hepatotoxicity. N Engl J Med 2006;354:731–9
   PubMed Web of Science ®Google Scholar
• Acharya N, Rosen AS, Polzer JP, D’Souza DN, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006;26:587–94
   Google Scholar